Key Takeaways
- Strong quarter, Revlimid cliff looms: India business rebounded to 7% YoY growth, North America hit $233 mn in revenue, and EMEU delivered its strongest quarter ever. But the second half loses Revlimid's margin cushion, and full-year EBITDA guidance was cut to 22.75%–24%.
- Tirzepatide is the new growth bet: The Yurpeak launch, exclusive with Eli Lilly, is called a "fairly material opportunity" with a dedicated field force already trained. Management won't quantify it yet, and the deal economics remain undisclosed.
- R&D spend is running hot, by design: At 7.1% of revenue, R&D is ~500 bps above plan, driven by accelerated filings and new pipeline additions in complex generics, respiratory, and peptides. This is investment, not leakage, but it pressures near-term margins.
- The U.S. pipeline is the Revlimid answer: Four major respiratory assets (including generic Advair) and three peptides are expected by CY26, but timing gaps before full benefit could sting. Lanreotide share is climbing toward 30%+ and Abraxane is beginning to pick up.
- What to watch next quarter: Whether the respiratory season delivers the promised Q3 uplift, the pace of Revlimid's decline, and any concrete tirzepatide launch date or revenue signal.
India Business: Recovery and the Obesity Bet
- One-India rebounded to 7% YoY growth after a weak Q1, when respiratory seasonality and new team formation slowed momentum. Chronic mix strengthened to 61.8%, with key therapies growing double digits: anti-diabetes 10%, cardiac 13%, urology 17%, dermatology 18%.
- Respiratory remains the cornerstone: triple combo products Voltido Trio Ciphaler and Foracort G are gaining strong traction, and Q3 is traditionally the best quarter for the category. Management expects to "capitalize maximum" on the season.
- Trade generics delivered strong double-digit growth on distribution execution, six new product launches, and technology investments. Consumer health continued its upward trajectory with Nicotex, Omnigel, and Cipladine holding #1 positions.
- GST rate transition caused a brief disruption in the sales trend, mostly resolved within the quarter. Management welcomed the government's reforms as a step toward healthcare affordability.
- Yurpeak (tirzepatide) is the flagship new launch: exclusive nationwide distribution rights from Eli Lilly, with a dedicated field force recruited and trained over 3–4 months. The product is supplied by Lilly and marketed by Cipla, with economics reflected in gross margin, but the specific sharing structure was not disclosed.
- Management sees tirzepatide as a distinct, superior option versus semaglutide, citing its dual GIP/GLP-1 agonist mechanism and faster innovator uptake. The opportunity is expected to be especially material in Tier 2 and Tier 3 towns.
- Semaglutide launch timing depends on approval: Cipla will evaluate launch once its file is approved and product can be supplied, which may be delayed beyond March/April. It will have a separate field force, not the tirzepatide team.
Achin Gupta: "This is tirzepatide is the first and only dual agonist of GIP and GLP-1, which makes it a very unique proposition. And while both products have been launched by the respective innovators, you can see from the uptake that the tirzepatide uptake is far ahead."
North America: Pipeline Building Against the Revlimid Decline
- Revenue reached $233 mn with Cipla emerging as the #1 player in the U.S. albuterol MDI market at 22% share. Lanreotide share rose to 22% (MAT Aug '25) and is expected to reach 30–35% as more capacity unlocks.
- Generic Revlimid is declining as expected: the quarterly trend is playing out per prior assumptions, and Q3 FY26 will see a very small contribution. Management declined to quantify the FY26 vs FY25 decline, citing confidentiality.
- The pipeline is designed to fill the gap: four major respiratory assets including generic Advair (Q4 CY26) and three peptide assets including liraglutide are expected to launch by calendar year 2026. Three of the four respiratory assets are filed from U.S. facilities, derisking the launches.
- Abraxane launch was slightly behind expectations because the market had extra stock at launch, but share has begun to pick up over the last 2–3 months. Management is working toward making it a high-share, sizable product but gave no percentage target.
- Filgrastim launched as Cipla's first U.S. biosimilar. The FDA's draft guidance potentially lowering biosimilar entry barriers has Cipla intending to add more products, both for its own portfolio and through partnerships. Current U.S. biosimilar pipeline: 2–3 internal products plus partnerships.
- Fall River capacity is being expanded for respiratory. U.S. manufacturing is more expensive than India primarily due to labor cost differentials; capex, material, and power costs are similar.
- The Bommasandra facility's FDA inspection from Q1 FY26 was classified as VAI during this quarter, a positive regulatory signal.
- Directionally, U.S. sales are headed toward $1 bn: on a run-rate basis, management expects to get there during next year, depending on launch and approval timing.
Umang Vohra: "Respiratory remains a cornerstone of our portfolio where we continue to invest with conviction."
International Markets: EMEU Shines, Africa Steady
- EMEU delivered its strongest quarterly revenue ever at $110 mn, up 15% YoY in USD terms, fueled by execution across DTM and B2B segments. Margin stability was maintained while leveraging internal pipeline assets. The top priority remains driving top-line growth through deeper penetration in core markets.
- One Africa grew 5% YoY in USD terms, with South Africa up 6% in ZAR. Private market secondary growth of 6.2% outperformed the market at 4.7%. Growth came from progress in key therapies, tender business expansion, and new launches.
- South Africa's next two quarters are critical for execution toward margin expansion. On tirzepatide, Lilly has already partnered with another player in South Africa for Mounjaro, and Novo Nordisk launched Ozempic on its own, so Cipla has no GLP-1 play there currently.
Margins: Revlimid Exit and R&D Investment Reshape the Profile
- First-half EBITDA margin sat at 25%+ with Revlimid's benefit. The second half will not have that benefit, and Q4 is usually the lowest quarter in both sales and margin. Full-year EBITDA margin guidance was revised down to 22.75%–24% from 23.5%–24.5%, excluding the yet-to-be-quantified Yurpeak business.
- Gross margin declined to 67%, with a sequential drop of 160–170 bps driven by three factors: some price decline in Q2, a pickup in Africa tender business (unevenly spread), and R&D material purchases sitting in material costs. Core gross margin is intact.
- R&D spend is running ~500 bps of revenue above plan, at 7.1% of revenue, driven by accelerated filings and new programs selected into the portfolio. For the full year, R&D will be about 0.5% of revenue higher than planned, covering complex generics, respiratory, oligos, and peptides.
- Expenses rose 11% YoY primarily on higher R&D investments including litigation costs, plus elevated marketing spend in line with sales growth.
- FY27 EBITDA margin direction was not given: management deferred, saying the budgeting exercise is underway and they may provide more guidance next quarter.
Ashish Adukia: "In the first half of the year, you had the benefit of Revlimid also sitting out there, which will not be there in the second half. So that is one reason for the first half being at 25-plus-percent and second half being based on the margin guidance that we have given."
Leadership Transition and Strategic Continuity
- Achin Gupta was introduced as designated CEO effective January 1, 2026, and will assume full responsibilities as CEO and MD from April 1, 2026. The transition signals continuity in strategy and therapeutic leadership.
- Management emphasized Cipla as an institution with continuity in purpose, access, and respiratory therapy leadership across segments built over years. The strategy does not change with the CEO transition.
Umang Vohra: "Cipla is an institution in and off by itself. So there will be continuity in what we are doing in terms of purpose, in terms of providing access in the leadership on respiratory therapy, in various segments that we've been building over the years."
Pipeline and Regulatory Milestones
- New India launches span multiple therapies: Yurpeak (tirzepatide, obesity), Doloneuron and Zolsoma (CNS, neuropathic pain and sleep), XTIKTR (urology, minimally invasive), and upcoming Elbicip (gastroenterology), Aprela (topical apremilast, psoriasis), plus anti-infectives Rizontem, Tedispan, Huena, ZEMDRI, and Cipenmet.
- U.S. approvals included generic glucagon and tentative approval for liraglutide through a partner, which could enable launch when exclusivity expires.
- Kemwell facility underwent a pre-approval inspection for a fill-finish product, not a biologic. The Indore facility expects reinspection anytime this year and early next.
- Management is evaluating internalizing fill and finish for certain product categories over time, though no timeline was given.
- Generic QVAR launch timeline was not disclosed: management said "it's in the court." Redihaler and QVAR are both independent files and both are opportunities.
Guidance & Commitments
| Commitment | Specifics | Timeline |
|---|---|---|
| India business growth | At or higher than India market growth rate | Q3 FY26 |
| Full-year EBITDA margin | 22.75% to 24% (revised from 23.5%–24.5%), excluding Yurpeak | FY26 |
| U.S. respiratory launches | Four major assets including generic Advair | Calendar year 2026 |
| U.S. peptide launches | Three assets including liraglutide | Calendar year 2026 |
| Lanreotide market share | Reach 30% or even 35% | No date; capacity-driven |
| U.S. $1 bn sales run rate | Achieve on a run-rate basis | During next year |
| R&D spend overrun | About 0.5% of revenue higher than planned | FY26 |
| Indore facility reinspection | Reinspection expected | Anytime this year and early next |
Key Metrics
| Metric | Q2 FY26 |
|---|---|
| Revenue | ₹7,589 cr, +8% YoY, highest ever quarterly revenue |
| EBITDA margin (excl. other income) | 25% |
| Gross margin after material cost | 67%, sequential decline of 160–170 bps due to product mix, R&D material purchases, and Africa tender business |
| Profit after tax | ₹1,351 cr, 17.8% of sales |
| Effective tax rate | 27% |
| R&D investment | ₹539 cr, 7.1% of revenue; full-year R&D now expected ~0.5% of revenue above original plan |
| Total expenses | ₹3,197 cr, +11% YoY, driven by R&D investments including litigation costs and elevated marketing spend |
| Net cash balance | ₹9,901 cr, after adjusting for over ₹400 cr dividend payout; debt including lease liability at ₹467 cr |
| Full-year EBITDA margin guidance | 22.75% to 24%, revised from 23.5% to 24.5%; excludes Yurpeak business plan |
| One-India revenue growth | +7% YoY |
| North America revenue | $233 million |
| U.S. albuterol MDI market share | 22%, Cipla emerged as number one player (IQVIA week ending Sep 19, 2025) |
| Lanreotide market share | 22% (MAT Aug '25) |
| EMEU revenue | $110 million, strongest quarterly revenue till date, +15% YoY in USD terms |
| One Africa revenue growth | +5% YoY in USD terms; South Africa +6% in ZAR terms |
| Chronic mix | 61.8% of branded prescriptions, strengthened YoY |
| Brands in INR 100 cr+ club | 29, 4 new brands added |
| Cipla unit sales in IPM | 200 cr+, only player at this volume level (IQVIA MAT Sep '25) |
| Chronic therapies CAGR | 16.4% from MAT Sep '21 to MAT Sep '25, revenues almost doubling |
| South Africa private market secondary growth | 6.2%, outperforming market growth of 4.7% |
| Generic Revlimid contribution | Virtually nil to very marginal expected in Q3 FY26; Q2 contribution lower than prior year but not much lower |
| U.S. revenue directional target | $1 billion next year, dependent on approval timing and launch cadence |